Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape
eLife · 2025
DOI: 10.7554/elife.95952 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Ashley L Cook und 16 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, United States. Hauptthemen laut MEDLINE: Nonsense Mediated mRNA Decay, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Swim Across America, American Society of Hematology.
Abstract (Originalsprache)
Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, United States.
- Cellular and Molecular Medicine Graduate Program, Johns Hopkins University School of Medicine, Baltimore, United States.
- Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, United States.
- Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, United States.
- Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, United States.
- Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, United States.
ORCID-Profile: Ashley L Cook, Surojit Sur, Chetan Bettegowda, Nicolas Wyhs
Förderung
- NCI NIH HHS
- Swim Across America
- American Society of Hematology
- Leukemia and Lymphoma Society
- Oncology Core CA
- Howard Hughes Medical Institute
- Ludwig Family Foundation
- Sol Goldman Charitable Trust
Zitieren
APA
Cook, A. L., Sur, S., Dobbyn, L., Watson, E., Cohen, J. D., Ptak, B., Lee, B. S., Paul, S., Hsiue, E., Popoli, M., Vogelstein, B., Papadopoulos, N., Bettegowda, C., Gabrielson, K., Zhou, S., Kinzler, K. W., & Wyhs, N. (2025). Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. eLife. https://doi.org/10.7554/elife.95952
Vancouver
Cook AL, Sur S, Dobbyn L, Watson E, Cohen JD, Ptak B, et al. Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. eLife. 2025. doi:10.7554/elife.95952
BibTeX
@article{Cook2025,
author = {Cook, Ashley L and Sur, Surojit and Dobbyn, Laura and Watson, Evangeline and Cohen, Joshua D and Ptak, Blair and Lee, Bum Seok and Paul, Suman and Hsiue, Emily and Popoli, Maria and Vogelstein, Bert and Papadopoulos, Nickolas and Bettegowda, Chetan and Gabrielson, Kathy and Zhou, Shibin and Kinzler, Kenneth W and Wyhs, Nicolas},
title = {Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.95952}
}
EUVIMED